FDA decision puts pelareorep in focus Oncolytics Biotech (NasdaqCM:ONCY) is back on investor radars after the FDA granted Fast Track Designation to pelareorep in a combination regimen for second line ...
Trump administration officials vetoed the FDA's plan to fast-track the review of a psychedelic treatment for severe ...
Stenoparib, targeting PARP1/2 and tankyrase 1/2, offers a unique mechanism for treating advanced ovarian cancer. The FDA's fast track designation facilitates expedited development and review, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results